Boston Scientific (NYSE:BSX) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Boston Scientific (NYSE:BSX - Get Free Report) released its quarterly earnings data on Wednesday. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03, Zacks reports. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the company posted $0.62 EPS. The company's revenue was up 22.8% compared to the same quarter last year. Boston Scientific updated its Q3 2025 guidance to 0.700-0.720 EPS.

Boston Scientific Trading Down 0.1%

Shares of BSX stock traded down $0.14 during trading hours on Friday, reaching $106.07. The company had a trading volume of 5,869,278 shares, compared to its average volume of 7,746,667. The company has a 50 day moving average of $103.58 and a 200 day moving average of $101.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The firm has a market cap of $156.92 billion, a price-to-earnings ratio of 63.14, a P/E/G ratio of 3.06 and a beta of 0.68. Boston Scientific has a 1-year low of $71.88 and a 1-year high of $108.94.

Wall Street Analysts Forecast Growth

BSX has been the topic of several analyst reports. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday. Truist Financial increased their price target on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Barclays increased their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $117.50.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president owned 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president directly owned 18,705 shares in the company, valued at $1,955,420.70. The trade was a 19.64% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 457,144 shares of company stock worth $47,296,288. Company insiders own 0.50% of the company's stock.

Institutional Trading of Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,376 shares of the medical equipment provider's stock after buying an additional 226 shares during the quarter. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.